INYVAX (project completed)

Optimisation of the Development of Poverty Related Diseases Vaccines by a transversal approach, addressing common gaps and challenges


A number of new vaccines are being developed against poverty-related infectious diseases of major global public health importance.

The development of these vaccines is facing the same kinds of challenges and gaps, which still prevent the following:

  1. Establishment of readily accessible formulation and scale-up process development capacity for neglected disease vaccines;
  2. Establishment of a systematic approach for prioritising formulation of vaccine candidates using accepted preclinical criteria;
  3. Development of information-sharing tools to strengthen connections between scientists, developers and clinical investigators.

These challenges include difficulties in accessing know-how and technology platforms in vaccine development, formulation and delivery, difficulties in harmonising safety data collection, and an insufficient number of trained scientists able to undertake leadership roles in vaccine development.


The overall goal of INYVAX is to improve access to vaccine technology spanning across different diseases by:

  • Developing knowledge-based platforms, i.e. for antigen optimisation, delivery systems and formulation;
  • Providing safety standards in clinical trials of Poverty Related Dideases (PRD) vaccines, allowing meta-analysis of the safety of similar vaccine approaches;
  • Generating training opportunities for PRD vaccine researchers.

This is achieved through five work packages (WP):

WP1 Comprehensive inventory of PRD vaccine technologies

WP2 Optimisation of knowledge and resources for the formulation of PRD vaccines

WP3 Implementation of safety standards in PRD vaccine clinical development

WP4 Advanced training in vaccinology for European and Developing Countries' scientists in relation to PRD vaccines (ADVAC)

WP5 Project coordination and management

Major milestones

Month 7: First training course in Vaccinology Advanced course in Vaccinology, ADVAC

Month 18: Strategy for optimisation of PRD vaccine technology

Month 19: Second course in Vaccinology, ADVAC

Month 24: Standard section on safety for PRD vaccine clinical trials protocols available

Month 31: Third course in Vaccinology, ADVAC

Month 36: To launch the database for the scientific PRD vaccine developers


Vaccine. 2013 Mar 11. doi:pii: S0264-410X(13)00230-2. 10.1016/j.vaccine.2013.02.041. PMID: 23499603